Diabetes drugs may be doing more than managing blood sugar, they could also shape cancer biology in unexpected ways.
New research is taking a closer look at how diabetes drugs may relate to cancer, with an emphasis on effects that go beyond lowering blood sugar or supporting weight control. Although diabetes has long been linked to a higher risk of certain cancers, scientists are still working to untangle how anti-diabetic medications might shape that risk.
In a new review, researchers evaluate evidence on several major drug classes, including metformin, SGLT2 inhibitors, and GLP-1 receptor agonists. The analysis describes how these medications could influence cancer progression by affecting how quickly cells multiply, how the immune system responds, how inflammation is regulated, and other underlying biological processes.
The findings point to possible therapeutic opportunities, but the authors emphasize that key questions remain unanswered.
Diabetes, Cancer Risk, and Unanswered Questions
Type 2 diabetes (T2DM) has been associated with an increased risk of multiple cancers, including liver, colorectal, and breast cancer. But the usual explanations, high blood sugar and excess weight, don’t tell the whole story.
That gap is pushing researchers to investigate: could the drugs used to treat diabetes also be shaping cancer risk through other biological routes?
Clarifying these effects could help determine when these drugs might offer protective benefits, when they may carry risks, and how they could fit into strategies for cancer prevention or treatment. Because the biology is complex, further studies are still needed to identify the key mechanisms involved.
Scope and Context of the Review
Published December 10, 2025 in the journal Clinical Precision Medicine, the review from Peking University People’s Hospital evaluates how three major diabetes drug classes, metformin, SGLT2 inhibitors, and GLP-1 receptor agonists, might influence cancer biology.
Rather than focusing only on blood sugar or weight, the authors summarize evidence that these medications can affect inflammation, immune responses, and cellular growth pathways that cancers rely on.
Mechanistic Insights From Preclinical and Clinical Evidence
The review systematically examines the preclinical and clinical evidence linking anti-diabetic medications to cancer. Metformin, one of the most widely used anti-diabetic drugs, is shown to influence cancer through various mechanisms, including enhancing anti-cancer immunity and inhibiting tumor growth by affecting the tumor microenvironment (TME).
It also modifies the activity of key cancer-related pathways like AMPK, mTOR, and PI3K/AKT, which are involved in cell proliferation, apoptosis, and angiogenesis.
Similarly, other medications like SGLT2 inhibitors and GLP-1 receptor agonists have shown potential in altering cancer cell proliferation, reducing inflammation, and promoting apoptosis. However, their effects vary depending on the type of cancer and specific drug used.
For example, while metformin has shown promise in reducing the risk of colorectal and liver cancers, its effects on breast cancer remain inconclusive.
Variable Effects and the Need for Further Research
Furthermore, the review highlights the importance of considering individual medications and their specific mechanisms of action, as well as the need for further clinical trials to confirm these findings and explore their therapeutic potential in cancer treatment.
According to Dr. Linong Ji, one of the leading researchers in this field, “While anti-diabetic medications are crucial in managing diabetes, their broader effects on cancer are still not fully understood. This review sheds light on the intricate mechanisms through which these drugs may influence cancer progression. However, the evidence is mixed, and we must continue to investigate the long-term impacts of these medications in cancer patients, as well as the potential for developing targeted therapies based on these findings.”
The findings from this review underscore the importance of personalized medicine in treating diabetic patients with cancer. Understanding the specific ways anti-diabetic medications influence cancer progression could lead to better-targeted treatments, improving both cancer prevention and patient outcomes.
This research also paves the way for future clinical trials to explore how existing medications can be optimized for cancer therapy or used as adjuncts to conventional treatments. The role of medications like metformin in cancer prevention could also inform public health strategies, particularly in managing diabetes and related comorbidities in populations at higher risk for cancer.
Reference: “Anti-diabetic medications and cancer: links beyond glycemic and body weight control” by Meng Cao, Chu Lin, Xiaoling Cai, Fang Lv, Wenjia Yang and Linong Ji, 7 November 2025, Precision Clinical Medicine.
DOI: 10.1093/pcmedi/pbaf028
This work was supported by the 2024 National Clinical Key Specialty Construction Program of China (Department of Endocrinology, Peking University People’s Hospital) with support from the central government budget, the Noncommunicable Chronic Diseases-National Science and Technology Major Project (grant Nos. 2023ZD0508200, 2023ZD0508205), the Clinical Medicine Plus X-Young Scholars Project of Peking University (grant No. PKU2025PKULCXQ025), and the Fundamental Research Funds for the Central Universities.
Never miss a breakthrough: Join the SciTechDaily newsletter.
Follow us on Google and Google News.
13 Comments
Seems more propaganda from Big Pharma vs actual results and truth of side effects
Every drug has potential side effects. It doesn’t mean you’re going to get them all.
What’s your evidence for that assertion?
Met formin is dirt cheap. Not a big pharma vector. The others truly do have surprisingly great promise in mechanism. Thanks.
How do you know this? Append your research please so we can all study it
Not enough treatments being released for cancer of all types for example isolated pro resolving mediators in studies with mice stopping the inflammation debris that occurs while cancer treatment that was killing the cancer now becomes non effective.
Also exact frequencies that are isolated killing certain cancers not talked or heavily developed.
Tumors being killed with less invasive tiny laser using MRI guided technology instead of serious surgery and many more methods never talked about just the promising drugs.
Factory food, junk food, pesticides, alcohol, drugs , stress, fungus, sugar… Is root of cancer.
I agree…..everything I’ve done in my life now have candida glabrata infection and fungal sinusitis
Accprding to me its all due to lifestyle no time limit for for food we eat .process food should stop only we have to take cooked food not more than 4hr dont preheated avoid chemical pestised grains and fruits.and main cause is excess using drugs the body cells damage and harmonal inbalance body will loose desies resistance.
Life style has a big impact I must agree. However it doesn’t explain why some babies/toddlers are born with cancer. There is some genetic components involved as well.
Could ya’ll make up yer minds! It works, it doesn’t work…all you so called experts are just using people as human guinea pigs…if you all were as smart as you think you are this would have been fixed years ago!
Well after all this time, you would think that very thing, however,…. This is just my opinion… A cure probably already exists… But there is so much money to be made, or shall I say wrapped up in research that no one wants to reveal that probability…$$$$$$$
Research is the key underfunding is the lock